Novo Nordisk announces significant reduction in US list price for Wegovy®, Ozempic®, and Rybelsus® (semaglutide medicines), building on continued efforts to expand access

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Feb. 24, 2026 /PRNewswire/ --Today, Novo Nordisk announced that, effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy ® (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic ® (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, and Rybelsus ® (semaglutide) tablets 7 mg or 14 mg to $675, representing reductions of approximately 50% and 35% for Wegovy ® and Ozempic ®, respectively, from the current list price. This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system.

"Lowering the list price of Wegovy ® and Ozempic ® is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. Private and public payers, as well as patients, want access and have been calling for lower list prices," said Jamey Millar, executive vice president, US Operations of Novo Nordisk. "Our actions today answer that call and remove cost barriers so the value of Wegovy ® and Ozempic ® can be realized by more patients. The lower list price is intended to connect more people with our innovative medicines, specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs."

Not all GLP-1s are the same. Semaglutide is the active ingredient in Wegovy ® and Ozempic ®, offering powerful efficacy and, unlike any other molecule in the GLP-1 class, it has FDA-approved medicines with a broad range of indications including: obesity (Wegovy ®), type 2 diabetes (Ozempic ®), type 2 diabetes and chronic kidney disease (Ozempic ® injection), and comorbid cardiovascular disease (Wegovy ® and Ozempic ®).

Through this action to lower list prices, Novo Nordisk seeks to improve access to these lifesaving medicines for even more patients and is the latest in a series of efforts from Novo Nordisk, making it easier and more affordable for people in the US to get authentic, FDA-approved Wegovy ® and Ozempic ® in the way that best fits their lives. This change does not impact other access efforts, including direct-to-patient, self-pay prices.

With the supply of all doses of these medicines fully available nationwide in the US, there is no reason for patients to gamble with their health with knock-off products produced by compounders. For more information about these efforts to protect patients, visit semaglutide.com.

What is Wegovy ®?

Wegovy ® (semaglutide) injection 1.7 mg or 2.4 mg and Wegovy ® (semaglutide) tablets 25 mg are prescription medicines used with a reduced calorie diet and increased physical activity to:

Wegovy ® (semaglutide) injection 1.7 mg or 2.4 mg is used with a reduced-calorie diet and increased physical activity to help children 12 years and older with obesity to lose weight and keep the weight off

Wegovy ® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.

It is not known if Wegovy ® injection is safe and effective:

It is not known if Wegovy ® tablets are safe and effective for use in people under 18 years of age.

Important Safety Information

What is the most important information I should know about Wegovy ®?

Wegovy ® may cause serious side effects, including:

Do not use Wegovy ® if:

Before using Wegovy ®, tell your healthcare provider if you have any other medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy ® may affect the way some medicines work and some medicines may affect the way Wegovy ® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy ® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

What are the possible side effects of Wegovy ®?

Wegovy ® may cause serious side effects, including:

The most common side effects of Wegovy ® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.

Please click here for Prescribing Information and Medication Guide for Wegovy ®.

What are Ozempic ® and Rybelsus ®?

Ozempic ® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg and Rybelsus ® (semaglutide) tablets 7 mg or 14 mg are prescription medicines used:

Ozempic ® is used:

Rybelsus ® is used:

It is not known if Ozempic ® and Rybelsus ® are safe and effective for use in children.

Important Safety Information

Do not share your Ozempic ® pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.

What is the most important information I should know about Ozempic ® and Rybelsus ®? Ozempic ® and Rybelsus ® may cause serious side effects, including:

Do not use Ozempic ® or Rybelsus ® if:

Before using Ozempic ® or Rybelsus ®, tell your healthcare provider if you have any other medical conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, herbal supplements. Rybelsus ® may affect the way some medicines work, and some medicines may affect the way Rybelsus ® work.

What are the possible side effects of Ozempic ® and Rybelsus ®?

Ozempic ® and Rybelsus ® may cause serious side effects, including:

The most common side effects of Ozempic ® and Rybelsus ® may include nausea, stomach (abdominal) pain, diarrhea, decreased appetite, vomiting, and constipation. When taking Rybelsus ®, they may also include decreased appetite.

Please click here for Prescribing Information and Medication Guide for Ozempic ® and here for Prescribing Information and Medication Guide for Rybelsus ®.

About Novo Nordisk

Novo Nordisk is a leading global healthcare company with a heritage of more than 100 years in diabetes care. Building on this foundation, our purpose is to drive change to defeat serious chronic diseases — from diabetes and obesity to rare blood and endocrine disorders — by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease. We are committed to long-term, responsible business practices that deliver financial, social and environmental value. Headquartered in Denmark and operating in around 80 countries, Novo Nordisk employs approximately 68,800 people and markets products in roughly 170 countries. In the United States, Novo Nordisk has a 40-year presence, is headquartered in New Jersey and employs approximately 10,000 people across more than 10 manufacturing, R&D, and corporate locations in eight states plus Washington, D.C. For more information, visit novonordisk.com and novonordiskus.com, and follow us on Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:

Liz Skrbkova (US)

+1 609 917 0632

[email protected]

Ambre James-Brown (Global)

+45 3079 9289

[email protected]

Investors:

Frederik Taylor Pitter (US)

+1 609 613 0568

[email protected]

Michael Novod

+45 3075 6050

[email protected]

Jacob Martin Wiborg Rode

+45 3075 5956

[email protected]

Sina Meyer

+45 3079 6656

[email protected]

Christoffer Sho Togo Tullin

+45 3079 1471

[email protected]

Max Ung

+45 3077 6414

[email protected]

SOURCE NOVO NORDISK INC.